Effect of BSD 2000 deep thermotherapy plus chemotherapy in treatment of malignant seroperitoneum of advanced epithelial ovarian cancer patients with drug resistance
10.3760/cma.j.issn.1006-9801.2015.06.012
- VernacularTitle:BSD2000相控阵聚焦热疗联合化疗治疗耐药性卵巢上皮癌患者恶性腹腔积液的效果
- Author:
Lang HE
;
Yonghong SUN
;
Shimin WEN
;
Hong CHEN
- Publication Type:Journal Article
- Keywords:
Ovarian neoplasms;
Hyperthermia,induction;
Drug therapy;
Seroperitoneum,malignant;
Drug resistance,neoplasm
- From:
Cancer Research and Clinic
2015;27(6):409-412
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect of BSD 2000 deep thermotherapy plus chemotherapy in treatment of malignant seroperitoneum of advanced epithelial ovarian cancer patients with drug resistance.Methods 36 advanced epithelial ovarian cancer patients with malignant seroperitoneum for drug resistance were randomly divided into two groups,trial group (18 cases) and control group (18 cases).Cases in trial group were treated with BSD 2000 deep thermotherapy plus GT regimen (gemcitabine 1 000 mg/m2 iv d1,d8,taxinol 80 mg/m2 ip d1,d8.28 days for a cycle),while control group with GT regimen alone.Effect,survival time (median) toxicity and Karnofsky score were evaluated after 2 cycles.Results Response rate (RR) was strongly higher in trial group compared with control group [55.6 ％ (10/18) vs 22.2 ％ (4/18),P ＜ 0.05],the same to disease control rate (DCR),but there was not significant difference between two groups (P ＞ 0.05).The improvement rate of Karnofsky score in trial group was higher than that in control group,which had no significance (P ＞ 0.05).The toxicity were similar in both groups,which had no stage 3 to 4 side-effect.The differences of survival time (median) and survival rate had no statistical significance between two groups (P ＞ 0.05).Conclusion It is useful to eliminate seroperitoneum,improve quality of life and decrease the toxicity for the regimen of BSD 2000 deep thermotherapy plus chemotherapy in treatment of malignant seroperitoneum of advanced epithelial ovarian cancer patients with drug resistance.
